Electrophysiology Studies for Cosmetic Surgeries — Cost, Top Hospitals & Success Rates | MyMedicPlus

An electrophysiology study (EPS) is an invasive diagnostic procedure performed by a cardiac electrophysiologist to assess the heart's electrical conduction system in detail. Unlike a standard ECG, which provides a surface view of cardiac electrical activity at rest, an EPS directly interrogates the intracardiac conduction pathways using thin, flexible catheters threaded through a vein — typically the femoral vein in the groin — and positioned at specific locations within the heart chambers under fluoroscopic (X-ray) guidance.

During the procedure, the electrophysiologist stimulates different areas of the heart with precisely timed electrical impulses to provoke and map arrhythmias that may not appear on surface monitoring. The study measures conduction intervals (such as the His-Purkinje conduction time and the sinus node recovery time), identifies the origin and re-entry circuits of tachycardias, and assesses the susceptibility to life-threatening ventricular arrhythmias including ventricular tachycardia (VT) and ventricular fibrillation (VF). An EPS typically takes 1–4 hours depending on the complexity of the arrhythmia being investigated.

EPS is often immediately followed by catheter ablation — a therapeutic procedure in which radiofrequency energy or cryotherapy is used to destroy the arrhythmia-causing tissue identified during the diagnostic phase. In this combined diagnostic-therapeutic scenario, the EPS guides real-time ablation therapy, eliminating or modifying the abnormal pathway. This combined approach has transformed the management of supraventricular tachycardias, Wolff-Parkinson-White syndrome, atrial flutter, and many forms of ventricular tachycardia.

Electrophysiology studies are indicated for the diagnostic workup of a broad range of cardiac arrhythmias. The primary conditions investigated include symptomatic supraventricular tachycardias (SVT) that are refractory to medication or where definitive ablation is planned, Wolff-Parkinson-White (WPW) syndrome and other accessory pathway-mediated tachycardias, unexplained syncope or pre-syncope suspected to be of arrhythmic origin, atrial flutter, and non-sustained or sustained ventricular tachycardia in patients with or without structural heart disease.

EPS is also indicated in risk stratification of patients with inherited arrhythmic syndromes such as Brugada syndrome, hypertrophic cardiomyopathy (HCM), long QT syndrome, and arrhythmogenic right ventricular cardiomyopathy (ARVC) — particularly to determine whether prophylactic implantable cardioverter-defibrillator (ICD) implantation is warranted. In patients who have survived sudden cardiac arrest or experienced haemodynamically unstable VT, EPS forms a critical component of the arrhythmia management workup alongside ICD assessment and antiarrhythmic drug titration.

Ideal candidates for EPS are patients with documented or suspected symptomatic arrhythmias who have not been adequately diagnosed through non-invasive testing (ECG, Holter monitoring, event recorders), patients with arrhythmias suitable for curative catheter ablation, and patients requiring risk stratification for sudden cardiac death in the context of structural heart disease or inherited arrhythmic syndrome. The ACC/AHA/HRS guidelines provide specific Class I and II recommendations for EPS indications.

Contraindications to EPS include active systemic infection or bacteraemia (due to the risk of endocarditis from intracardiac catheter manipulation), uncontrolled heart failure or cardiogenic shock, severe uncorrected coagulopathy or anticoagulation that cannot be temporarily reversed, and patient refusal of the procedure. Relative contraindications include recent acute myocardial infarction within 48 hours, severe symptomatic aortic stenosis, and severe peripheral vascular disease limiting femoral venous access. Renal function must be assessed prior to the procedure as contrast agents may be used.

The conventional EPS employs multi-electrode catheters (typically 4–10 poles) positioned in the right atrium, His bundle region, right ventricle, and coronary sinus. Programmed electrical stimulation protocols are used to induce the target arrhythmia under controlled conditions. Three-dimensional electroanatomical mapping systems (CARTO, EnSite) are now widely used in complex ablation procedures, generating a 3D geometry of the cardiac chamber and displaying activation sequences in real time, enabling highly precise ablation with minimal fluoroscopy exposure.

For specific conditions, variations include intracardiac echocardiography (ICE) guidance for transseptal puncture in left-sided ablation procedures, cryoablation as an alternative to radiofrequency energy (particularly favoured in paediatric SVT and pulmonary vein isolation for atrial fibrillation), and stereotactic arrhythmia radioablation (STAR) — a non-invasive approach using stereotactic body radiation therapy for scar-related VT in patients too sick for catheter ablation. For risk stratification rather than ablation, EPS may be combined with pharmacological provocation testing using isoproterenol, procainamide, or ajmaline depending on the suspected syndrome.

Advanced mapping systems — CARTO (Biosense Webster) and EnSite Precision (Abbott) — create high-density three-dimensional maps of the chamber of interest with thousands of points, identifying arrhythmia substrates and critical isthmuses that guide ablation catheter positioning. Intracardiac echocardiography (ICE) guides transseptal puncture and monitors catheter contact. In paediatric patients and those with congenital heart disease, EPS protocols are modified to account for different anatomical variants and arrhythmia substrates.

Electrophysiology studies provide definitive diagnosis of arrhythmia mechanisms that cannot be reliably established non-invasively. When combined with catheter ablation, EPS-guided procedures achieve cure rates of 90–97% for common SVTs such as AVNRT (atrioventricular nodal re-entrant tachycardia) and AVRT (atrioventricular re-entrant tachycardia via accessory pathway), significantly superior to lifelong antiarrhythmic medication. For typical atrial flutter, ablation of the cavotricuspid isthmus achieves acute success rates exceeding 95%.

For ventricular tachycardia in ischaemic cardiomyopathy, EPS-guided catheter ablation reduces VT recurrence and appropriate ICD shocks by approximately 50–70% compared to medical therapy alone in contemporary multicentre trials. For unexplained syncope due to sinus node dysfunction or conduction system disease, EPS identifies the cause in 30–50% of cases where non-invasive evaluation has been unrevealing, enabling targeted pacemaker implantation or medical management. The ability to definitively diagnose and often simultaneously treat the arrhythmia in a single procedure represents a major advantage over empirical antiarrhythmic drug therapy.

EPS is a low-to-moderate risk invasive procedure with an overall major complication rate of less than 1–2% in experienced electrophysiology laboratories. Vascular access complications — including haematoma, arteriovenous fistula, or pseudoaneurysm at the femoral puncture site — are the most common adverse events, occurring in approximately 0.5–1% of cases. Cardiac complications include cardiac tamponade (pericardial effusion requiring drainage) occurring in less than 0.5% of cases, and inadvertent catheter-induced complete heart block (rare, estimated at 0.1%).

Deep vein thrombosis and pulmonary embolism are uncommon but recognised risks of prolonged catheter instrumentation. For left-sided ablation procedures requiring transseptal puncture or aortic retrograde access, stroke risk (approximately 0.1–0.5%) must be discussed with the patient. Radiation exposure from fluoroscopy is minimised with 3D mapping systems but remains a consideration, particularly in paediatric patients and in women of childbearing age. Mortality from EPS procedures is extremely rare in experienced centres, estimated at less than 0.1%.

Following EPS (with or without ablation), patients are monitored in a cardiac recovery area for 4–6 hours to ensure stable haemodynamics and assess the vascular access site for haematoma or bleeding. Patients are typically discharged the same day or the following morning after an overnight observation stay if the procedure was complex or if ablation was performed. Bed rest with leg immobilisation for 3–4 hours post-procedure is standard when femoral venous access was used.

Outpatient follow-up with the electrophysiologist is typically scheduled at 4–6 weeks post-procedure to review symptoms, assess ablation success (absence of arrhythmia recurrence), and arrange any necessary device or medication adjustments. A 12-lead ECG and Holter monitoring may be performed at the follow-up visit. Patients are advised to avoid strenuous physical activity for 48–72 hours post-procedure and to watch for signs of haematoma, bleeding, or infection at the access site. After successful SVT ablation, antiarrhythmic medications can typically be discontinued, which represents a major quality-of-life improvement for most patients.

Electrophysiology study costs are driven primarily by the complexity of the procedure (diagnostic EPS alone versus combined EPS with ablation), the type of mapping system used (conventional fluoroscopy vs. 3D electroanatomical mapping), the specific arrhythmia (simple SVT ablation vs. complex VT ablation), surgeon experience, and geographic location. In the United States, a combined EPS and catheter ablation procedure for SVT costs USD 15,000–50,000 including hospital, physician, and equipment fees. In the United Kingdom under private care, similar procedures cost GBP 8,000–25,000.

In leading cardiac centres in India (Chennai, Mumbai, Delhi, Hyderabad, Bangalore), EPS with SVT ablation costs USD 2,000–6,000 at JCI or NABH-accredited hospitals equipped with modern 3D mapping systems and experienced electrophysiologists trained at international centres. In Thailand, costs are USD 4,000–10,000. In Turkey, USD 3,000–8,000. Patients travelling for EPS and ablation to India typically save 60–80% compared to US or UK costs while accessing equivalent-quality care with no waiting time.

For patients who are not candidates for EPS or who prefer non-invasive management, antiarrhythmic drug therapy remains an important alternative. Medications such as flecainide, propafenone, sotalol, and amiodarone can suppress many arrhythmias, though they carry long-term toxicity profiles and do not provide cure. Rate control with beta-blockers or calcium channel blockers is preferred for atrial fibrillation where rhythm control is not the primary goal.

External cardioversion (synchronised DC shock) is an alternative to ablation for terminating sustained atrial or ventricular tachycardia episodes but does not prevent recurrence. For patients with VT related to structural heart disease who are not ablation candidates, ICD implantation provides life-saving therapy but does not prevent VT — it terminates episodes when they occur. Wearable cardioverter-defibrillators are used as bridging therapy in selected high-risk patients. The choice between EPS with ablation and pharmacological management depends on arrhythmia type, patient preference, and institutional expertise.